Clinical Trial Update: Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer [NA]

View source ↗

Summary

Clinical trial evaluating vitamin B12 for aromatase inhibitor–associated musculoskeletal symptoms in hormone receptor-positive breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Vitamin B12 (cobalamin)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: HR-positive Breast Cancer | NA | Status: WITHDRAWN